Nuvation BioNUVB +3.10%33 EV-to-FCF is -11.63 as of Jul. 08, 2026. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 327 Biotechnology companies, Nuvation Bio ranks worse than 305810.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nuvation Bio's Enterprise Value is $1,559.0 Mil.
Nuvation Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-134.1 Mil. Therefore, Nuvation Bio's EV-to-FCF for today is -11.63.
The historical rank and industry rank for Nuvation Bio's EV-to-FCF or its related term are showing as below:
NUVB'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.82 Med: -2.69 Max: -0.27
Current: -11.63
During the past 6 years, the highest EV-to-FCF of Nuvation Bio was -0.27. The lowest was -13.82. And the median was -2.69.
NUVB's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs NUVB: -11.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nuvation Bio's PE Ratio (TTM) for today is calculated as:
Nuvation Bio's share price for today is $5.846.
Nuvation Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nuvation Bio EV-to-FCF Related Terms
Nuvation Bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvation Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's EV-to-FCF falls into.
Nuvation Bio's current Enterprise Value is $1,559.0 Mil.
Nuvation Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-134.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB) has a EV-to-FCF of -11.63 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nuvation Bio and its competitors. According to the industry distribution chart, Nuvation Bio ranks #999999 out of 327 companies in the Biotechnology industry.
Is Nuvation Bio's EV-to-FCF too high?
Nuvation Bio's current EV-to-FCF is -11.63. Based on the distribution chart, Nuvation Bio ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's EV-to-FCF compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #999999 out of 327 companies for EV-to-FCF. This places Nuvation Bio in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current EV-to-FCF is -11.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current EV-to-FCF of -11.63. The current EV-to-FCF is -11.63. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current EV-to-FCF is -11.63 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
